A Phase-3b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety and Efficacy of Conivaptan in Symptomatic Acute Decompensated Heart Failure (ADHF) Subjects With Hyponatremia.

Trial Profile

A Phase-3b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety and Efficacy of Conivaptan in Symptomatic Acute Decompensated Heart Failure (ADHF) Subjects With Hyponatremia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2014

At a glance

  • Drugs Conivaptan (Primary)
  • Indications Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms CONVERT-H
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 18 Sep 2009 Actual end date (Aug 2009) and actual number of patients (9) added as reported by ClinicalTrials.gov.
    • 18 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Jul 2009 Additional location (India) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top